- Home
- DYAI vs CCEL Comparison
DYAI vs CCEL Comparison
Compare DYAI & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- CCEL
- Stock Information
- Founded
- DYAI 1979
- CCEL 1989
- Country
- DYAI United States
- CCEL United States
- Employees
- DYAI N/A
- CCEL N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- CCEL Managed Health Care
- Sector
- DYAI Health Care
- CCEL Health Care
- Exchange
- DYAI Nasdaq
- CCEL Nasdaq
- Market Cap
- DYAI 54.4M
- CCEL 50.0M
- IPO Year
- DYAI 2004
- CCEL 1997
- Fundamental
- Price
- DYAI $1.50
- CCEL $7.40
- Analyst Decision
- DYAI Strong Buy
- CCEL
- Analyst Count
- DYAI 1
- CCEL 0
- Target Price
- DYAI $6.00
- CCEL N/A
- AVG Volume (30 Days)
- DYAI 213.3K
- CCEL 13.7K
- Earning Date
- DYAI 11-12-2024
- CCEL 02-26-2025
- Dividend Yield
- DYAI N/A
- CCEL 3.38%
- EPS Growth
- DYAI N/A
- CCEL N/A
- EPS
- DYAI N/A
- CCEL N/A
- Revenue
- DYAI $3,364,548.00
- CCEL $31,838,476.00
- Revenue This Year
- DYAI $51.30
- CCEL $3.97
- Revenue Next Year
- DYAI $73.26
- CCEL $0.91
- P/E Ratio
- DYAI N/A
- CCEL N/A
- Revenue Growth
- DYAI 13.82
- CCEL 1.95
- 52 Week Low
- DYAI $0.93
- CCEL $4.47
- 52 Week High
- DYAI $2.67
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- DYAI 42.12
- CCEL 46.30
- Support Level
- DYAI $1.45
- CCEL $6.74
- Resistance Level
- DYAI $1.79
- CCEL $7.50
- Average True Range (ATR)
- DYAI 0.24
- CCEL 0.42
- MACD
- DYAI -0.05
- CCEL -0.02
- Stochastic Oscillator
- DYAI 7.25
- CCEL 56.42
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.